跳到正文
原文
The Lancet 柳叶刀· Amit Goel, Sumit Rungta, Vinod Kumar, Shalimar, Ajay Kumar, Harshita Katiyar, Surender Singh, Amar Deep, Ajay Kumar Mishra, Ashish Awasthi, Vikasendu Agarwal, Anurag Kumar Tiwari, Dawesh Prakash Yadav, Sunit Kumar Shukla, Ujjwal Sonika, Radha Krishan Dhiman, Bharat Bhushan Rewari, Rakesh Aggarwal·· 2026-10-01精选AI 评分70

RESOLVE研究:8周对比12周sofosbuvir-velpatasvir治疗初发非肝硬化慢性丙肝的随机对照试验

[Articles] 8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India

AI 导读

RESOLVE研究(一项在印度开展的多中心、开放标签、优效性随机对照试验)结果显示,8周sofosbuvir-velpatasvir方案在治疗初发且无肝硬化的慢性丙肝患者中的疗效与标准12周方案相似。这一发现支持在此类患者中缩短治疗时长。

推荐理由

研究验证8周sofosbuvir-velpatasvir方案在治疗初发非肝硬化丙肝中的疗效,为缩短标准治疗周期提供随机对照数据支持。

来源:The Lancet 柳叶刀 · thelancet.com